Windtree Therapeutics expects data useful for an end of Phase 2 meeting.
1 report, 0 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Windtree Therapeutics expects data useful for an end of Phase 2 meeting.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Windtree Therapeutics (United States)
company in Philadelphia, United States
Nothing else this week.
Related events
- Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.
- BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
Coverage
Newest first; wire copies grouped- Unknown outlet